news
Roche Annual General Meeting 2015
4 March 2015 | By Roche
Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...
List view / Grid view
Roche
news
Roche’s Avastin plus chemotherapy receives positive recommendation from CHMP for EU approval in advanced cervical cancer
2 March 2015 | By Roche
Combination of Avastin and chemotherapy would be the first new treatment in advanced cervical cancer to extend life in nearly a decade...
news
Roche extends tender offer for Foundation Medicine, Inc.
2 March 2015 | By Roche
Roche announced that it has extended the expiration of its tender offer to purchase up to 15,604,288 of the outstanding common shares of Foundation Medicine, Inc...
news
FDA grants Roche’s cobimetinib priority review for use in combination with Zelboraf (vemurafenib) in advanced melanoma
19 February 2015 | By Roche
Roche announced the U.S. Food and Drug Administration has accepted and granted priority review for the company’s New Drug Application for cobimetinib in combination with Zelboraf® (vemurafenib) for the treatment of people with BRAF V600 mutation-positive advanced melanoma...
news
FDA approves Roche’s Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
9 February 2015 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, in people with diabetic macular edema...
news
Roche’s Phase III study of Gazyva/Gazyvaro showed significant benefit in refractory indolent non-Hodgkin’s lymphoma
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...
news
Roche spends $1.03 billion for majority stake in Foundation Medicine
3 February 2015 | By Roche
Roche today announced that it has commenced a cash tender offer for up to 15,604,288 outstanding shares of common stock of Foundation Medicine, Inc. at a price of $50.00 per share...
news
FDA grants Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A
2 February 2015 | By Roche
US FDA has granted Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer...
news
Roche delivers solid results in 2014
28 January 2015 | By Roche
Pharmaceutical giant Roche delivers its 2014 year-end results...
news
Roche opens new Learning Center in Kaiseraugst
19 January 2015 | By Roche
Today Roche opened its new Learning Center in Kaiseraugst. Besides offering a superlative infrastructure for trainees, the Learning Center contains a state-of-the-art school laboratory, which in this form is unparalleled in Switzerland...
news
Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need
16 January 2015 | By Roche
Roche announced that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France...
news
Perjecta (pertuzumab) and Kadcycla (trastuzumab emtansine) remain available through Cancer Drugs Fund, but Avastin (bevacizumab) denied
13 January 2015 | By Porter Novelli Limited
Roche welcomes the announcement from NHS England that patients can continue to access our breast cancer medicines Perjeta, Kadcyla and Avastin via the Cancer Drugs Fund (CDF), but is extremely disappointed that patients with advanced bowel and ovarian cancer will now be denied Avastin on the NHS, following their review…
news
Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
19 December 2014 | By Roche
Roche announced top-line results of the Phase III MARIANNE study...
news
Changes in Roche Board of Directors and enlarged Corporate Executive Committee
12 December 2014 | By Roche
At its December meeting, the Board of Directors (BoD) of Roche Holding recommended first proposals for approval by the AGM, scheduled for 3 March 2015...
news
Roche’s preeclampsia test helps to predict this life-threatening condition in pregnant women at risk
10 December 2014 | By Roche
New data demonstrate high prognostic value of Elecsys blood test...
